Skip to content

Enable Communication

Opportunity

Clinical trial participants will likely not feel engaged with the clinical trial if they are not informed about what matters to them (e.g., trial progress) at an appropriate frequency. Providing relevant information through a method that meets their needs and preferences could improve participant engagement, compliance and retention. Value can be gained where participants can choose how and when they receive communications.

Considerations to Help Action the Opportunity

  • Partner with patient organizations and sites to identify the types of information that participants would like (e.g., gratitude, trial progress) and the preferred method and frequency for sharing of information 
  • Define the settings (e.g., in-person or self-reviewed), mediums (e.g., written, audio or visual), delivery methods (e.g., paper, email, WhatsApp / text, portal / app), preferred language, and frequency (e.g., weekly, monthly, annually) for the communications
  • Utilize the settings, mediums and methods that work for the participant population and ideally provide multiple options to suit the spectrum of participant needs (e.g., to account for country or age preferences) 
  • Define design considerations that factor in the participant or site needs, such as font sizes, consistent formatting and ‘branding’
  • Develop a participant communication plan that captures participant preferences and delivers communications accordingly 
  • Define the timing and requirements of obtaining Ethics Committee (EC) approval (e.g., submit any templates at the start of the study outlining the type of communication planned) on participant facing materials and the method of delivery

Value and Potential Benefits

  • Increases understanding and engagement in the trial if participants receive communications that are relevant to them in a preferred format and frequency
  • Allows participants to have the information they require, while avoiding overwhelming or burdensome communications
  • Allows participants to feel appreciated and valued for their involvement in the study
  • Potentially increases trial participant retention (avoid drop-outs) and compliance (higher motivation) 

Related Blog Posts

A New Era in Advancing Care for Pregnant and Breastfeeding Patients

One major challenge facing the clinical research ecosystem is not whether, but how to study drug safety and efficacy in pregnant and breastfeeding populations. A growing number of organizations—including the ICH E21 Expert Working Group (EWG) and TransCelerate’s Interpretation of Pharmacovigilance Guidances & Regulations  (IGR PV) initiative—are diligently seeking ethical and responsible solutions to protect these…

Improving Medicine Use During Pregnancy & Breastfeeding: Forging a Path Forward   

The scientific community intended to protect pregnant and breastfeeding populations when it strictly limited their involvement in clinical trials after the thalidomide crisis of the 1950s-1960s. Yet over the past few decades, people have increasingly recognized the real-life challenges posed by the lack of research into the safety of medications used during pregnancy and breastfeeding.…

Transforming Pharmacovigilance: Solutions to Solve Regulatory Challenges

Patient safety depends partly on sponsor organizations’ compliance with pharmacovigilance (PV) regulatory requirements—even when global variations exist. Helping sponsors interpret and operationalize challenging PV regulations and guidances is the goal of TransCelerate’s Interpretation of Pharmacovigilance Guidances & Regulations (IGR PV) initiative. In this third installment of our IGR PV blog series, we will examine the solutions…